Abstract
The link between apoptosis and malignant cell growth is firmly established, and various forms of therapy in cancer, e.g., the use of DNA-damaging chemotherapeutic drugs, are based on the principle of inducing apoptosis in malignant cells. However, in many known instances, tumor cells develop resistance to apoptosis through various mechanisms. Thus, interventions designed to facilitate tumor cells apoptosis are likely to have a therapeutic benefit. PKCθ, which is expressed relatively selectively in T cells, plays an important role in mature T cell activation and proliferation upon its translocation to the plasma membrane. PKCθ is necessary for induction of the interleukin-2 (IL-2) gene because the transcription factors AP-1 and NF-kB, which are essential for IL-2 gene promoter activation, are main targets of PKCθ. Recent studies revealed that PKCθ provides an important survival signal that protects leukemic T cells from Fas- or UV-induced apoptosis. These findings and the constitutive localization of PKCθ in the membrane of some leukemic T cells suggests that it plays a role in leukemic T cell survival and / or proliferation, and that selective PKCθ-inhibitory strategies may facilitate elimination of malignant T cells. The high-affinity IL-2 receptor (IL-2Rα) is a major target of receptor-directed therapy in several human diseases, and it is constitutively expressed by the malignant cells in some T cell leukemias, suggesting an autocrine IL-2 / IL-2R loop that participates in the expansion of leukemic IL-2R+ cells. Therefore, given the essential role of PKCθ in IL-2 production, IL-2 gene regulation by PKCθ could also be of therapeutic interest.
Keywords: pkco, t cell leukemia, ap-I, nf-kb, Il-2r, Il-2r cells
Current Cancer Drug Targets
Title: Protein Kinase C-θ (PKCθ), a Potential Drug Target for Therapeutic Intervention with Human T Cell Leukemias
Volume: 2 Issue: 2
Author(s): Martin Villalba and Amnon Altman
Affiliation:
Keywords: pkco, t cell leukemia, ap-I, nf-kb, Il-2r, Il-2r cells
Abstract: The link between apoptosis and malignant cell growth is firmly established, and various forms of therapy in cancer, e.g., the use of DNA-damaging chemotherapeutic drugs, are based on the principle of inducing apoptosis in malignant cells. However, in many known instances, tumor cells develop resistance to apoptosis through various mechanisms. Thus, interventions designed to facilitate tumor cells apoptosis are likely to have a therapeutic benefit. PKCθ, which is expressed relatively selectively in T cells, plays an important role in mature T cell activation and proliferation upon its translocation to the plasma membrane. PKCθ is necessary for induction of the interleukin-2 (IL-2) gene because the transcription factors AP-1 and NF-kB, which are essential for IL-2 gene promoter activation, are main targets of PKCθ. Recent studies revealed that PKCθ provides an important survival signal that protects leukemic T cells from Fas- or UV-induced apoptosis. These findings and the constitutive localization of PKCθ in the membrane of some leukemic T cells suggests that it plays a role in leukemic T cell survival and / or proliferation, and that selective PKCθ-inhibitory strategies may facilitate elimination of malignant T cells. The high-affinity IL-2 receptor (IL-2Rα) is a major target of receptor-directed therapy in several human diseases, and it is constitutively expressed by the malignant cells in some T cell leukemias, suggesting an autocrine IL-2 / IL-2R loop that participates in the expansion of leukemic IL-2R+ cells. Therefore, given the essential role of PKCθ in IL-2 production, IL-2 gene regulation by PKCθ could also be of therapeutic interest.
Export Options
About this article
Cite this article as:
Villalba Martin and Altman Amnon, Protein Kinase C-θ (PKCθ), a Potential Drug Target for Therapeutic Intervention with Human T Cell Leukemias, Current Cancer Drug Targets 2002; 2 (2) . https://dx.doi.org/10.2174/1568009023333908
DOI https://dx.doi.org/10.2174/1568009023333908 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adult Stem Cells and Skeletal Muscle Regeneration
Current Gene Therapy Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) A Computational Study of the Oligosaccharide Binding Sites in the Lectin-Like Domain of Tumor Necrosis Factor and the TNF-derived TIP Peptide
Current Pharmaceutical Design Platelets: Angels and Demons Dancing on the Immune Stage. Nutrition Conducts the Orchestra
Endocrine, Metabolic & Immune Disorders - Drug Targets Progress Toward Understanding the Nature and Function of C-H...O Interactions
Current Organic Chemistry Pharmacotherapy in Neonatal and Pediatric Extracorporeal Membrane Oxygenation (ECMO)
Current Drug Metabolism Membrane Bioreactors in Food, Pharmaceutical and Biofuel Applications: State of the Art, Progresses and Perspectives
Current Organic Chemistry cGMP-Dependent Protein Kinase in Regulation of the Pulmonary Circulation
Current Respiratory Medicine Reviews Synthesis and Biological Evaluation of Mutual Prodrugs of Carboxylic Group Containing Some Non-Steroidal Anti-Inflammatory Drugs and Propyphenazone
Current Drug Delivery Cross-Talk Between the Androgen Receptor and the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Brain Inflammation Following Intracerebral Hemorrhage
Current Neuropharmacology Patent Selections
Recent Patents on Drug Delivery & Formulation Phytosterols: Perspectives in Human Nutrition and Clinical Therapy
Current Medicinal Chemistry The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Erythropoiesis Stimulating Agents and Techniques: A Challenge for Doping Analysts
Current Medicinal Chemistry Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Synthetic Lethality: From Research to Precision Cancer Nanomedicine
Current Cancer Drug Targets Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer
Current Cancer Drug Targets Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued)